Jamie Smith
Media Relations
Email: jamie.smith@molnlycke.com
Phone: +46 723 757507
Mölnlycke Health Care breaks ground on $135 million expansion of Wound Care manufacturing facility in Brunswick, Maine
Brunswick, Maine, USA and Gothenburg, Sweden. 23 September 2025. Mölnlycke® Health Care, a global leader in MedTech, headquartered in Gothenburg, Sweden, today celebrates the groundbreaking of a major expansion to its wound care manufacturing capacity in Brunswick, Maine. This milestone marks the beginning of a $135 million investment aimed at significantly increasing Mölnlycke’s manufacturing capacity in the United States.
“This expansion is a bold step forward for Mölnlycke in the U.S. It reinforces our mission to free patients and caregivers from the burden of wounds, strengthens supply resilience, and helps us to deliver high-quality wound care solutions faster, smarter, and more sustainably,” says Zlatko Rihter, CEO of Mölnlycke. “I’m proud to mark this milestone for Mölnlycke, for Maine and for the future of MedTech.”
The expansion is part of Mölnlycke’s strategic commitment to localise production and meet growing demand from U.S. healthcare providers. The state-of-the-art facility will support Mölnlycke’s long-term sustainability goals by using renewable energy solutions, including wind and solar power, and streamlined logistics. It will also feature advanced machinery sourced from U.S. suppliers.
Over the next five years, the investment will create new job opportunities, increasing Mölnlycke’s workforce in Maine by approximately 10%, and will engage local contractors and suppliers. Mölnlycke’s ambition with the Brunswick expansion, is to enable for more patients in the U.S. to benefit from cutting-edge innovative and high-quality wound care products produced by Mölnlycke.
“Today isn’t just about breaking ground. It’s about being bold, embracing partnerships and leading with passion,” says Chris Biddle, General Manager of U.S. Manufacturing, Wound Care. “Thank you to everyone who helped bring this vision to reality. The expansion is a win for Mölnlycke, for the local community and, ultimately, for the patients we serve.”
The groundbreaking ceremony was attended by senior federal and state lawmakers, including US Senator for Maine, Angus King, and Maine Governor, Janet Mills, who offered their support for the investment.
Note to editors
More information, including press materials and multimedia assets, is available in Mölnlycke’s online media room at Media room: Mölnlycke Brunswick, Maine site expansion
For more information, please contact:
Latest news
-
5 million and growing: scaling Granudacyn® production in Salzburg
-
First factory in China reaches key milestone and strengthens Mölnlycke’s global manufacturing network
Mölnlycke has completed construction of its first manufacturing facility in China, marking a major milestone in the company's growth journey and strengthening its ability to serve one of the world's largest and fastest growing healthcare markets.
-
Mölnlycke Health Care accelerates U.S. growth journey with three wound care product launches
Peachtree Corners, GA. 7 July, 2026. Mölnlycke Health Care (Mölnlycke®), a global leader in MedTech, has launched three product innovations in the U.S. since the start of 2026. Designed to expand access to advanced wound care solutions and strengthen the company’s U.S. presence, the portfolio expansion also supports long-term value creation across key market segments.
-
Changes to Mölnlycke Health Care Board of Directors
Gothenburg, Sweden. 23 June 2026. Mölnlycke Health Care (Mölnlycke®), a global leader in MedTech, today announces changes to its Board of Directors. Christian Cederholm will leave his Board assignment, while Filippa Stenberg will take his place as member of the Board. Thomas Kidane will step in as deputy board member.
-
Mölnlycke Health Care strengthens global manufacturing footprint to power future growth in wound care
Gothenburg, Sweden. 8 June 2026. Mölnlycke Health Care (“Mölnlycke®”), a global leader in MedTech, today confirmed a combined investment of approximately EUR 40 million in Mikkeli, Finland, and Oldham, UK. The investments strengthen the company’s global wound care manufacturing network by increasing capacity, optimising process quality and enhancing supply chain resilience and sustainability.
-
Mölnlycke Health Care and Zhende Medical form pioneering joint venture to expand access to advanced wound care solutions in China
Gothenburg, Sweden, and Shanghai, China. 21 May 2026.
Mölnlycke Health Care (“Mölnlycke®”), a global leader in MedTech and advanced wound care solutions, and Zhende Medical, a leading supplier of medical care and protection in China, today announce the formation of a new joint venture company in China to accelerate growth in one of the world’s fastest-growing wound care markets. The joint venture, majority-owned by Mölnlycke, will integrate the two companies’ wound care portfolios and commercial capabilities to offer healthcare providers, patients and the public expanded access to advanced treatments, improved care delivery and better patient outcomes across China. -
Simple glove change could save the NHS £45 million over five years and improve caesarean safety
Gothenburg, Sweden. 27 April 2026. A new study1 published in the Journal of Hospital Infection shows that introducing a simple glove change during caesarean birth could deliver millions in cost savings for the National Health Service (NHS) in England.
-
Mölnlycke Health Care announces Andreas Johansson as Interim Chief Financial Officer
Gothenburg, Sweden. Wednesday 15 April 2026. Mölnlycke Health Care announces today the appointment of Andreas Johansson as Interim Chief Financial Officer (CFO), with immediate effect.
-
Mölnlycke Health Care annual report 2025 highlights sustainable growth and strategic transformation
Gothenburg, Sweden. 1 April 2026. Today, Mölnlycke Health Care has published its annual report 2025, including sustainability report, outlining the company’s continued focus on revolutionising care for people and planet.